Oculis Holding AG (OCSAW)

Market Cap	1.06B
Revenue (ttm)	847,333
Net Income (ttm)	-116.41M
Shares Out	52.06M
EPS (ttm)	-2.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.71
Previous Close	n/a
Day's Range	0.71 - 0.71
52-Week Range	1.80 - 11.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 10, 2025

About OCSAW

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: OCSAW
• Website: https://oculis.com